Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 890 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast - Male Clear all

Conditions: Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma
Interventions: AZD6750, rilvegostomig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more

Conditions: Breast Cancer
Interventions: trastuzumab, carboplatin, cyclophosphamide, melphalan, thiotepa, adjuvant therapy, autologous-autologous tandem hematopoietic stem cell transplantation, bone marrow ablation with stem cell support, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Up to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Duarte, California

Conditions: Cardiovascular Diseases, Breast Cancer, Prostate Cancer, Physical Inactivity
Interventions: Gamification and Social Support, Attention control; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Duarte, California • Philadelphia, Pennsylvania

Conditions: Renal Cell Carcinoma, Gastric Cancer, Metastatic Breast Cancer, Small-cell Lung Cancer, Other Solid Tumors
Interventions: HC-5404-FU; Drug
Lead sponsor: HiberCell, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Detroit, Michigan • Saint Paul, Minnesota • Dallas, Texas + 1 more

Conditions: Breast Cancer
Interventions: Herceptin, NeuVax vaccine, GM-CSF; Drug
Lead sponsor: George E. Peoples; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 29
States / cities: Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 22 more

Conditions: Breast Carcinoma, Male Breast Carcinoma, Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Ovarian Carcinoma, Pancreatic Exocrine Neoplasm, Stage IVB Prostate Cancer American Joint Committee on Cancer v8, Triple-Negative Breast Carcinoma
Interventions: Best Practice, Educational Intervention, Electronic Health Record Review, Genetic Counseling, Interview, Survey Administration; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Los Angeles, California • Rochester, New York

Conditions: Vaginal Atrophy, Sexual Dysfunction, Vaginal Dryness, Dyspareunia
Interventions: Hybrid Fractional Laser; Device
Lead sponsor: Sciton; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cancer
Interventions: vorinostat; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms
Interventions: PF-06952229, Enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 15
States / cities: Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more

Conditions: Breast Cancer, Cardiac Toxicity
Interventions: Coreg CR®, lisinopril, placebo; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 174
States / cities: Long Beach, California • Sylmar, California • Aurora, Colorado + 142 more

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: sorafenib tosylate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Advanced Cancers
Interventions: Atorvastatin, Fish Oil Supplement, Placebo; Drug · Dietary Supplement · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Localized Breast Cancer, Localized Prostate Cancer, Patients Receiving External Beam Radiotherapy
Interventions: Organic Germanium, Placebo; Dietary Supplement
Lead sponsor: Arizona Oncology Services; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Breast Cancer, Prostate Cancer
Interventions: HER2 FPBMC; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cancer
Interventions: palivizumab, ribavirin; Biological · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Gynecomastia
Interventions: Zeltiq Coolsculpting System; Device
Lead sponsor: Dermatology, Laser & Vein Specialists of the Carolinas; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Cancer
Interventions: infection prophylaxis and management; Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 12 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer
Interventions: AZD6244, Dacarbazine, Erlotinib, Docetaxel, Temsirolimus; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2025
U.S. locations: 4
States / cities: Detroit, Michigan • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more

Conditions: Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
Interventions: tucatinib, trastuzumab, fulvestrant; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 76
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more

Conditions: Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Liver Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Skin Neoplasm, Metastatic Malignant Solid Neoplasm, Resectable Lung Non-Small Cell Carcinoma, Early Stage Lung Non-Small Cell Carcinoma, Resectable Malignant Solid Neoplasm, Resectable Triple-Negative Breast Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Recurrent Cervical Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Tissue Collection; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Brain Metastases, Adult
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: Sarah Sammons, MD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer
Interventions: Isosulfan blue, Axillary Lymph Node Dissection, Surgery, Sentinel Lymph Node Biopsy, Thoracoscopic Surgery, Technetium Tc 99m Sulfur Colloid; Drug · Procedure · Radiation
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 120 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: pegfilgrastim, AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 3,294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2027
U.S. locations: 539
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 369 more

Conditions: Breast Cancer, Colorectal Cancer, Fatigue, Lung Cancer, Pain, Prostate Cancer
Interventions: educational intervention, questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications, fatigue assessment and management, quality-of-life assessment, standard follow-up care; Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Duarte, California

Search by objective public record fields.

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)

A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Access to Genetic Testing in Underserved Patients With Cancer

Randomized, Controlled Trial With Hybrid Fractional Laser

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

Sorafenib in Treating Patients With Metastatic Breast Cancer

Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer

Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

Targeted Fat Reduction of Pseudogynecomastia in the Male Breast Using the ZELTIQ Coolsculpting System

Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Neoadjuvant Immunotherapy in Brain Metastases

Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Pain and Fatigue Management in Patients With Breast Cancer, Prostate Cancer, Colon Cancer, or Lung Cancer